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Abstract
Background: The mechanisms of drug-induced visions are poorly understood. Very few serotonergic hallucinogens have
been studied in humans in decades, despite widespread use of these drugs and potential relevance of their mechanisms to
hallucinations occurring in psychiatric and neurological disorders.
Methodology/Principal Findings: We investigated the mechanisms of hallucinogen-induced visions by measuring the
visual and perceptual effects of the hallucinogenic serotonin 5-HT2AR receptor agonist and monoamine releaser, 3,4-
methylenedioxyamphetamine (MDA), in a double-blind placebo-controlled study. We found that MDA increased self-report
measures of mystical-type experience and other hallucinogen-like effects, including reported visual alterations. MDA
produced a significant increase in closed-eye visions (CEVs), with considerable individual variation. Magnitude of CEVs after
MDA was associated with lower performance on measures of contour integration and object recognition.
Conclusions/Significance: Drug-induced visions may have greater intensity in people with poor sensory or perceptual
processing, suggesting common mechanisms with other hallucinatory syndromes. MDA is a potential tool to investigate
mystical experiences and visual perception.
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Introduction
Serotonergic hallucinogens —such as LSD, mescaline, and
psilocybin— produce a bewildering variety of visual phenomena
[1–7]. Visual changes include altered form and depth perception,
prolonged afterimages, motion-processing impairments, vivid
pseudo-hallucinations, and, only very rarely, actual hallucinations
in which insight into the non-veridical nature of the experience is
impaired [8–17]. Pseudo-hallucinations can occur both with the
eyes closed (closed-eye visions, CEVs) and open (open-eye visions,
OEVs). Few studies have attempted to address the mechanisms of
these visual changes after hallucinogens.
In order to study drug-induced visual hallucinations, we adminis-
tered 3,4-methylenedioxyamphetamine (MDA, tenamfetamine, ‘‘Love
Drug’’) to healthy drug-experienced volunteers. MDA is a hallucinogen
[18] that acts as a serotonergic 5-HT2A receptor agonist [19] and
releases monoamines by interacting with monoamine plasmalemmal
transporters [20–22]. MDA has been used non-medically since the
1960s and was scheduled as a controlled substance in the US in 1970.
Some of what is sold as ‘‘Ecstasy’’ contains MDA instead of MDMA.
For example, in a sample of 107 illicit Ecstasy tablets, Baggott and
colleagues [23] found that 6.5% contained MDA. Similarly, MDA was
found in 0.6% of pills submitted to Forensic Science South Australia
(FSSA) for testing by South Australia Police (SAPOL) over a 6-month
period [24]. Despite appearing in illicit drug preparations, MDA has
not been studied in humans in over 30 years [3,25–29]. Early reports
suggest MDA may have more consistent emotional effects than
hallucinogens such as LSD [30] and animal drug discrimination studies
confirm that MDA has both typical hallucinogenic (LSD-like) effects as
well as unusual effects similar to those of 3,4-methylenedioxymetham-
phetamine (MDMA) [31,32], which some consider to represent a novel
class of pharmacological agent (‘‘entactogen’’ [18]). Animal studies
show that MDA shares with MDMA potential to cause long-term
serotonergic neurotoxicity [33].
Hallucinations are usually explained by some combination of
three factors, none of which are mutually exclusive: loss of sensory
or perceptual ability, abnormally increased neural activity, or
cognitive alterations [34–39].
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tions is loss of sensory or perceptual ability. Poor vision and perceptual
difficulties increase risk for visual hallucinations [40]. Visual risk
factors include low-level visual difficulties such as reduced contrast
perception [41–44] and higher-level visual form perception deficits
[45–48]. Among many other deficits, impairments in contour
detection are seen in individuals with schizophrenia [49–54] and
in people under the influence of the NMDA antagonist hallu-
cinogen ketamine [55].
A second factor potentially contributing to hallucinations is
abnormally increased neural activity, as in the case of migraine aura or
epilepsy [39,56–59]. Hallucinations may sometimes arise from
abnormal activity in the cortex [60–62], possibly involving
abnormal interactions between brain areas [35]. Serotonergic
hallucinogens likely alter the balance of excitation and inhibition
in the cortex [63], changing activity of brain networks [64], by
affecting 5-HT2A and other serotonergic receptors [65–68].
Resulting excitation, according to formal models of hallucination
developed by Ermentrout and Cowan [63] and others [69–71],
could lead to activation of spatially periodic patterns in the cortex,
which could be perceived as visual phenomena.
A third factor that may contribute to drug-induced hallucina-
tions is alterations in cognitive functions – such as altered balance of top-
down and bottom-up information [37] or impairment in
perceptual inference [72] – which could lead to increased
acceptance of expectations as reality. This possible mechanism
can be tested by providing top-down cues for recognizing images.
Appropriate top-down knowledge can enable recognition of an
object from an otherwise unrecognizable degraded image [73–75]
and, more generally, context facilitates object recognition [76–78].
Hypotheses
We predicted that MDA would induce self-report hallucinogen
effects and that self-report visual changes would be accompanied
by changes in one or more perceptual tasks designed to measure
factors potentially contributing to hallucinations.
Methods
The protocol for this trial, supporting CONSORT checklist,
and CONSORT flowchart are available as supporting informa-
tion; see Protocol S1, Checklist S1 and Figure S1.
Ethics statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. All participants provided written
informed consent. The protocol was approved by the Institutional
Review Boards at the University of California, San Francisco, and
the California Pacific Medical Center Research Institute.
General study design for MDA experiment
This double-blind, placebo-controlled within-subjects crossover
study was carried out at the UCSF Clinical Research Center at
San Francisco General Hospital with participants admitted to the
hospital for a single three-evening stay. Extensive safety monitor-
ing was carried out from before drug administration until after
drug effects resolved. Participants returned to the laboratory two
weeks after discharge to ensure residual toxicity was not present.
Participants were twelve healthy individuals with self-report
experience with either MDA alone or experience with both
MDMA and a hallucinogen, such as LSD. None had any DSM-IV
drug dependence diagnoses (other than nicotine or caffeine).
Comprehensive safety screening procedures included history &
physical, self-report drug history, 12-lead EKG, liver panel, and
blood chemistry. Participants were asked to practice effective
contraception during the study. Pregnancy and drug toxicology
tests were performed before drug administration. Nicotine was
forbidden during the hospital stay and caffeine was forbidden
starting ten hours before dosing.
Racemic MDA was synthesized by the researchers with identity
and purity confirmed using melting point, proton nuclear
magnetic resonance (300 MHz), and elemental analysis under an
FDA Investigational New Drug application.
Experimental drug administration occurred after a 2-hour fast
to minimize individual variance in drug absorption. Lactose in a
gelatin capsule was used for the placebo. MDA was administered
in a dose of 98 mg/70 kg body weight in a gelatin capsule
identical to the placebo. Drug and placebo dosing occurred on
consecutive days.
Timed measurements included blood samples for pharmacoki-
netic purposes, physiological measures of heart rate and blood
pressure, self-report measures of drug effects, and computerized
tasks. Only measures relevant to visual changes and global
hallucinogen effects are described in this paper. Other measures
will be described in a separate manuscript.
Self-report measures
We used visual analog items (VAS) to measure the time course
of rapidly changing general drug effects and visual changes. Self-
report measures of general drug effects were the items ‘‘any drug
effects’’, ‘‘good drug effects’’, ‘‘bad drug effects’’, and ‘‘high’’. Self-
report measures of drug-induced visual changes were the visual
analog items ‘‘when I close my eyes I see complex abstract
patterns’’ (hereafter shortened to ‘patterns’), ‘‘when I close my eyes
I see objects or non-living things’’ (‘things’), ‘‘when I close my eyes
I see animals, people, or beings’’ (‘beings’), and ‘‘when I close my
eyes I see places or landscapes’’ (‘scenes’). Participants used the
mouse to slide a mark along a line that was labeled at the left and
right extremes with the phrases ‘‘Not at All’’ and ‘‘Extremely’’,
respectively. Participants closed their eyes for 30 seconds before
answering the visual questions. This interval was timed by
computer, which provided an auditory cue to re-open the eyes.
Self-report measures were made before drug administration and at
0.5, 1, 2, 2.5, 3, 4, 6, and 8 hours after drug administration.
Maximum post dose changes (Emax) were used as the primary
outcome measures. In order to examine relationships with other
outcome measures, summary measures of peak general drug
effects and peak visual changes were made by averaging Emax for
the four questions in each of those two categories.
To allow comparisons with past studies of hallucinogens (e.g.,
[79]), we measured MDA effects with two self-report question-
naires, the Altered States of Consciousness (ASC) and the Hood
Mysticism questionnaires. We used an English-translation of three
scales from the ASC, a widely used visual analog self-report
questionnaire assessing primary aspects of altered states of
consciousness [80,81]. Each of the three primary scales is
comprised of several item clusters. The 17-item ‘‘Oceanic
Boundlessness’’ (OB) scale measures positively experienced
derealization and depersonalization accompanied by changes
sense of time. 21-item ‘‘Dread of Ego Dissolution’’ (DED) scale
measures negatively experienced derealization and depersonaliza-
tion, such as loss of self-control, thought disorder, arousal, and
anxiety. The 18-item ‘‘Visionary Changes’’ (VC) scale measures
alterations in perception and meaning. The perceptual and
cognitive changes measured by the VC are particularly diagnostic
of hallucinogens. Thus, we report scores for the VC item clusters:
simple visuals (which includes macropsia/micropsia and CEVs),
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reminiscence, and imagination.
To assess possible mystical-type experiences, we selected the
self-report Mysticism scale developed by Hood [82] from the work
of Stace [83]. The 32-item questionnaire has cross-cultural
generalizability and is widely used in studying the psychology of
religion [84,85] and, more recently, has been used in psycho-
pharmacology [79]. Three empirically derived factors were
measured: interpretation (corresponding to three mystical dimen-
sions described by Stace: positive mood, noetic quality, and
sacredness); introvertive mysticism (corresponding to the Stace
dimensions of internal unity, transcendence of time and space, and
ineffability); and extrovertive mysticism (corresponding to the
dimension of the unity of all things/all things are alive). Items were
rated on a four-point scale (1=this description is extremely not
true of my own experience or experiences; 4=this description is
extremely true of my own experience or experiences), with an
additional option for ‘‘I cannot decide.’’
The ASC and Hood were given at 7.5 hrs after drug
administration. Participants were asked to answer for the entire
time period following drug administration.
Tilt illusion task
We selected the tilt illusion (TI), a widely studied orientation-
based visual illusion, to investigate possible abnormally increased
neural activity in early visual processing [86,87]. The TI occurs
when viewing a test line or grating against a background or
surround of similar stimuli with different orientation from the test
stimulus. This causes an orientation-dependent shift in the
perceived orientation of the test stimulus, as illustrated in
Figure 1. The TI is thought to be the result of lateral inhibition
between orientation-selective cortical neurons in the occipital
cortex [88–94]. Formal models of the primary visual cortex can
reproduce the TI [95,96] and indicate that altering the balance of
excitation in the cortex may alter the magnitude of the TI. Thus, if
hallucinogens cause hallucinations by altering the balance of
excitation and inhibition in the cortex one would predict
simultaneous increases in the TI.
To estimate the strength of the tilt illusion (TI), we had
participants determine if a two-dimensional, contrast-varying sine
wave within a circular window was tilted to the left or right
(Figure 1). We then varied the orientation of a surrounding
grating, which changed the magnitude and direction of the TI. We
determined the point of subjective verticality twice (using two one-
up-one-down staircases with 0.5u step sizes) for each of the
following surround orientations: 240u, 230u, 220u, 215u, 210u,
10u,1 5 u,2 0 u,3 0 u, and 40u. Three staircases without any surround
were included to establish a baseline subjective vertical. Interwo-
ven staircases terminated after six reversals and point of subjective
verticality was estimated as the average of the last four reversals.
Participants were tested binocularly, seated approximately
0.110 m away from a 19 in. Dell monitor in a dimly lit testing
room. Monitor resolution was set to 10246768 pixels. Each trial
began with a 500 ms mask circular stimulus composed of random
pink noise intended to decrease any effects of previous trials. This was
replaced by the target and, if present, the surround, both of which
were presented until the participant made an untimed judgment
about whether the central target was tilted left or right. Target was
1.2u diameter. Surround was 5.2u diameter. Both were 1.7 cpd.
For each administration of the task, we determined mean
points-of-subjective-verticality (PSV) for each surrounding orien-
tation and then corrected for variation in head angle by
subtracting the mean baseline ‘no surround’ PSV. The magnitudes
of the tilt illusion for individuals and conditions were then
estimated by taking the difference between the minimum and
maximum PSV.
Contour integration task
We used a contour detection task to assess potential hallucino-
gen-induced changes in perceptual ability. Ability to detect
contours is thought to rely on neural interactions in early visual
cortex, including V1 [97–99], and impairments are seen in
individuals with schizophrenia [49–54] and in those under the
influence of ketamine (e.g., [55]). If decreased sensory or
perceptual ability is a factor in drug-induced hallucinations, then
one would predict that performance on contour-detection tasks
would be impaired by hallucinogens and that individuals with
lower baseline performance on these tasks should have increased
susceptibility to drug-induced hallucinations.
We used a contour integration task to measure perceptual
organization. Stimuli were closed chains of Gabor gratings in an
egg-like shape that was obscured by a background of evenly-
spaced randomly-oriented Gabor gratings (Figure 2). The egg-
like shape pointed left or right and participants made an
unspeeded two-alternative forced-choice (2AFC) about the shape’s
orientation using a keyboard. Different levels of difficulty were
created by varying the orientation jitter of the background
distracter gratings.
Figure 1. Illustration of the tilt illusion. Central gratings are both oriented vertically, but appear to many observers to be tilted in the opposite
direction of surrounding gratings (which are tilted 10u from vertical).
doi:10.1371/journal.pone.0014074.g001
Hallucinogenic Effects of MDA
PLoS ONE | www.plosone.org 3 December 2010 | Volume 5 | Issue 12 | e14074The carrier spatial frequency of the Gabor gratings was 5 c/deg
and their contrast was 95%. Space between contour gratings was
eight times the wavelength of the Gabor gratings. Average spacing
of distracter background gratings was 90% that of contour
gratings. Spacing of contour gratings and the average spacing of
distracter background gratings were kept constant.
Participants were tested binocularly, seated approximately 0.11 m
away from a 19 in. Dell monitor in a dimly lit testing room. Monitor
resolution was set at 8006600 pixels. Images subtended 9.4u of visual
angle vertically and 12.4u of visual angle horizontally from the testing
distance. Stimuli were presented for 2 seconds. A fixation point on a
gray background was shown at the beginning and end of after each
trial. Images were presented in five blocks of increasing orientation
jitter, varyingbetween 7uand 24ua cr o s st h ef i v ed i ff i cu l t yle v e ls(7 – 8 u,
11–12u, 15–16u, 19–20u, 23–24u). There were twenty trials in each
block. Due to a computer error, the 23–24u jitter difficulty level was
repeated in nine participants. These extra measurements were
included in the analysis.
To analyze contour integration results, we used a generalized
linear model with the 2-AFC logit function from the Psyphy R
library to individually estimate a psychometric function for each
subject and session [100]. Threshold (defined as 75% accuracy)
orientation jitter was then used as the dependent measure in
statistical models.
Object recognition task
An object recognition task in which participants must recognize
degraded images of common objects was designed to assess both
perceptual organization and hypothesized impairments in ability
to use top-down information to facilitate recognition of drawings.
In such a task, accurate cues should improve performance and
inaccurate cues potentially impair performance. If the mechanism
of drug-induced hallucinations involves increased efficacy of top-
down influences of perception, then there should be drug effects
on both true and false cues, widening differences in accuracy.
Alternatively, weakened top-down influence should reduce this
cueing effect.
Stimuli were black-and-white drawings of objects placed on a
random noise background. Images were modified from the
Rossion and Pourtois [101] set of images, which were developed
as a copyright free and improved alternative to the commercial
Snodgrass set. Images converted to black-and-white and all placed
on an identical 2886288 pixel 1/F
2 noise background, which was
chosen to approximate the spectral characteristics of natural
scenes [102].
To vary difficulty in a controlled fashion, we used the Random
Image Structure Evolution [75] technique to progressively distort
the images. Images were first subjected to a two-dimensional fast
Fourier transform. The amplitudes of all images were averaged
together. This mean amplitude was then used in place of the
original amplitude for each picture and recombined with each
picture’s phase information. Reverse fast Fourier transforms were
used to reconstitute the images. These reconstituted images all had
the same frequency spectrum and differed only in phase. Thus,
potential low-level differences between images were minimized. In
order to degrade the images, we progressively shifted the phases of
each image to/from the mean phase in steps of 5%, taking
precautions to avoid zero crossings that would produce disconti-
nuities. Four levels of image degradation are illustrated in
Figure 3.
Pilot recognition experiments were conducted in 10 healthy
volunteers in order to identify images that were particularly easy or
difficult to identify. 120 images were retained for use. These were
divided into six groups of comparable difficulty, which were
counterbalanced across participants with respect to drug condition
and cue type.
The task, which required approximately 40 minutes, included
60 images at each administration. Equal numbers of images were
Figure 2. Sample contour integration stimuli. Sample contour integration stimuli showing egg-shaped contours in an easily discriminable no
jitter condition (left top) and a more difficult condition in which contour elements have been randomly jittered by 11–12u (left bottom). On the right,
the same stimuli are shown without the randomly oriented background Gabor patches, illustrating how these ‘noise’ elements impair contour
recognition by eliminating density cues.
doi:10.1371/journal.pone.0014074.g002
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answer); false cues (a wrong answer); or no cue. Thus, cues were
correct half of the time.
The task was administered at 3 hours after dosing. Participants
were tested binocularly, seated approximately 0.11 m away from a
19 in. Dell monitor in a dimly lit testing room. Monitor resolution
was set to 10246768 pixels. Stimuli were presented for 2 seconds.
A fixation point on a gray background was shown at the beginning
and end of after each trial.
Participants initiated each trial by pressing a key. Each trial then
began with a cue. The cue consisted of a word (ora series of thirteen
X characters, in the case of a no cue trial). After 1 second, the image
stimulus was added below the cue. After 2 seconds, the cue and
image disappearedand a question appearedaskingif theparticipant
could identify the image (‘‘Do you know what it was? Y or N?’’). If
the participant did not believe they could identify the image, it was
shown again in the next trial at a lower level of degradation. Images
were initially shown with 87.5% distortion and decreased by 5%
until participant reported they could identify the image or 12.5%
distortion was reached. They or the researcher then typed in the
named object. After this, the correct name and an undistorted
version of the image appeared. The primary outcome measures of
this task were recognition accuracy and level of distortion at which
participants thought they could identify images. These were
calculated separately for each cue type.
Statistical Analysis
Data were analyzed using mixed-effects models in R [103] with
drug condition as a fixed-effect and participant as a random effect
using a 2-tailed 0.05 level of significance. In order to control for
possible sequence effects, linear models initially included a
dummy-coded term for dosing sequence and a sequence-condition
interaction term. When repeated measures were made (as in the
case of self-report measures), data were transformed into
maximum effects (Emax) for analysis. Summary statistics for the
fixed-effects part of the model were calculated with the anova
function in R. After a significant F-test, pairwise comparisons were
made using Tukey’s post hoc tests.
Results
Participant demographics are described in Table 1. MDA was
well tolerated by all participants and produced psychological
effects consistent with hallucinogenic action along with robust
physiological changes. Participants frequently reported euphoric
mood, altered sense of reality and time, and feelings of awe and
contentedness.
Self-report measures
MDA had significant effects on participants’ maximum ratings
(Emax) of all four general drug effects VAS measures: any drug
effects (t=18.624, p,0.001); bad drug effects (t=2.366,
p=0.0272); good drug effects (t=9.769, p,0.001); and high
(t=13.35, p,0.001). Individuals’ mean responses for these four
questions are plotted for the two conditions in Figure 4.
Approximately half the participants reported significant closed-
eye visions (CEVs) on the four visual changes VAS measures.
CEVs were generally absent during the placebo session (with the
exception of one participant, who reported seeing beings and
Figure 3. Sample object image at four levels of degradation.
doi:10.1371/journal.pone.0014074.g003
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condition on participants’ Emax for all four visual questions:
closed-eye patterns (t=4.437, p,0.001), closed-eye objects
(t=3.883, p,0.001); closed-eye beings (t=2.54, p=0.019); and
closed-eye scenes (t=2.79, p=0.011). Individuals’ mean responses
for these visual questions are plotted in Figure 5. This variation in
CEVs was probably not just due to variation in general drug
effects, as there was no correlation between mean Emax for visual
questions and mean Emax for general drug effects. There was also
no significant effect of dosing sequence.
Because anthropological evidence suggests that abstract visuals
such as patterns occur before semantically-meaningful visuals
during hallucinogen inebriation [1], we examined whether time of
maximum change varied between patterns and other categories.
However, a linear mixed-effects model comparing the time of
maximum change between questions for the six individuals
reporting the greatest visual changes was not significant. Group
means for patterns and the other three visual VAS questions are
depicted in Figure 6.
MDA significantly increased all main ASC and Hood scales
compared to placebo. There were also significant effects in all VC
subscales, indicating characteristic hallucinogen effects, such as
synesthesia. See Figure 7.
Tilt illusion task
One participant had unusable data on their first session (placebo)
because they misunderstood the direction of the judgments being
made, preventing the staircase from converging on a threshold.
The magnitude of the tilt illusion was not significantly affected
by dosing condition (F1, 9=2.515, p=0.147), but there was a
significant effect of dosing sequence (F1, 9=6.658, p=0.030) in a
mixed-effects model containing the two terms and their interac-
tion. Individuals who received MDA first showed larger tilt
illusions than those receiving it second (average magnitude for
both sessions was 10.5 degrees vs. 7.0 degrees), consistent with
potential residual effects increasing the tilt illusion on their day 2
placebo session (Figures 8 and 9). We therefore made a model
where dosing condition predicted the tilt illusion in session one
only. There was a significant effect of dosing condition
(F1,9=7.495, p=0.023), with MDA increasing the tilt illusion
over placebo (11.3 degrees vs. 6.8 degrees).
There was no significant effect of peak CEVS on magnitude of
the tilt illusion. Similarly, there was no significant effect of peak
geometric CEV when this self-report item was analyzed separately.
Contour integration task
One participant was excluded from the analysis of contour
integration because their performance never exceeded chance.
There was no significant effect of dosing sequence or days elapsed
since last exposure to an MDMA-like drug. Dosing condition
alone did not predict threshold orientation jitter (F1,10=0.409,
p=0.537). However, when peak CEVs was added as a predictor,
there was a significant main effect of CEVs (F1,9=9.385,
p=0.014) and a significant interaction with dosing condition
(F1,9=17.972, p=0.022). This relationship is depicted in
Figure 10. In contrast, peak general drug effects did not
Table 1. Demographics of randomized participants.
Subject Age Gender Race Ethnicity
Years of Educa-
tion Completed
Weight
(kg) BMI
MDA Dose
(mg)
Past Drug
Experience
1 20 Male Hispanic
or Latino
White 13 63.5 19.8 89 MDMA
Hallucinogens
2 22 Male Not Hispanic
or Latino
White 13 77.6 22 109 MDA
MDMA
Hallucinogens
3 20 Male Not Hispanic
or Latino
White 13 82.1 25.2 115 MDMA
Hallucinogens
4 38 Male Hispanic
or Latino
Black or African
American
14 91.2 23.8 128 MDMA
Hallucinogens
5 32 Male Not Hispanic
or Latino
White 17 76.7 22.3 107 MDA
MDMA
Hallucinogens
6 23 Male Not Hispanic
or Latino
White 14 81.6 22 114 MDMA
Hallucinogens
7 26 Male Not Hispanic
or Latino
White 18 74.8 23 105 MDMA
Hallucinogens
8 29 Male Not Hispanic
or Latino
White 18 72.1 22.8 101 MDA
MDMA
Hallucinogens
9 39 Male Not Hispanic
or Latino
White 18 65.8 20.8 92 MDMA
Hallucinogens
10 43 Female Not Hispanic
or Latino
White 14 59 20 83 MDMA
Hallucinogens
11 21 Male Not Hispanic
or Latino
White 13 65.8 22.7 92 MDMA
Hallucinogens
12 21 Male Not Hispanic
or Latino
White 13 78.9 22 110 MDA
MDMA
Hallucinogens
doi:10.1371/journal.pone.0014074.t001
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simple accuracy was used as the dependent measure.
Object recognition task
Data were missing for one individual’s MDA session due to a
computer error. There was no significant effect of dosing sequence
on object recognition accuracy. A linear mixed-effects model
where accuracy was predicted by cue type and dosing condition
resulted in main effects of cue type (F2,52=6.035, p=0.004) and
condition (F1,52=6.058, p=0.017), but no interaction. Accuracy
on trials with true cues was estimated to be 7.2% higher than in
either no or false cue trials. Accuracy on MDA was estimated to be
Figure 4. Time course of self-report general drug effects. Drug effects were calculated by averaging baseline-corrected scores for the visual
analog items ‘‘any drug effects’’, ‘‘good drug effects’’, ‘‘bad drug effects’’, and ‘‘high’’.
doi:10.1371/journal.pone.0014074.g004
Figure 5. Time course of self-report closed-eye visuals. Closed-eye visual effects were calculated by averaging baseline-corrected scores for
the visual analog items ‘‘when I close my eyes I see complex abstract patterns’’, ‘‘when I close my eyes I see objects or non-living things’’, ‘‘when I
close my eyes I see animals, people, or beings’’, and ‘‘when I close my eyes I see places or landscapes’’.
doi:10.1371/journal.pone.0014074.g005
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level to the model revealed significant effects of degradation level
(F1,46=4.334, p=0.043) and an interaction of dosing condition
and degradation level (F1,46=6.693, p=0.013), indicating that
participants on MDA were more impaired by image degradation.
Examining only the accurate trials, we constructed a mixed-
effects model predicting the degradation level at which stimuli
were correctly identified. This also revealed significant main effects
of dosing condition (F1,52=6.3148, p=0.0151) and cue type
(F2,52=43.3203, p,.0001) on degradation level of correct
identification, though there was again no significant interaction.
We then collapsed across cue types and attempted to find a
relationship between performance and self-report visual change.
We found significant main effects of CEVs (F1,10=20.337,
p=0.001) and condition (F1,9=8.736, p=0.016), as well as a
significant interaction term (F1,9=11.499, p=0.008), in predicting
accuracy. Increased CEVs reduced accuracy for MDA and
placebo, 0.2% and 0.1%, respectively, for each percent increase
in CEVs. This effect is significantly larger for MDA than placebo
(t=3.391, p=0.008). See Figure 12 for a depiction of this
relationship. This relationship appeared to be specific to visual
effects rather than general drug effects, as peak general drug effects
was not significant when added to the statistical model. Similarly,
there was no significant effect of dosing sequence. Unlike accuracy,
degradation level for correct trials was not significantly predicted
by CEVs.
Discussion
We conducted the first controlled study of the hallucinogen
MDA in humans in over thirty years [27]. Participants reported
that MDA administration was followed by a number of
prototypical hallucinogen effects, as indicated by significant
increases in our visual change VAS items, ASC VC subscales,
and the Hood Mysticism questionnaire. Along with perceptual and
cognitive changes, the potential for mystical-type experiences has
long been considered a characteristic of hallucinogens (e.g., [104]).
However, to our knowledge, this is only the second published
controlled experiment [79,105] to assess a hallucinogen using a
well-validated measure of mystical-type experience and the first
such publication involving a hallucinogen other than psilocybin.
Figure 6. Group means for categories of closed-eye visuals
after MDA.
doi:10.1371/journal.pone.0014074.g006
Figure 7. Effects of MDA on Hood Mysticism and Altered State of Consciousness scales.
doi:10.1371/journal.pone.0014074.g007
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approach of using MDA to understand hallucinogen-induced
visions despite the caveat that MDA has complicated pharmacol-
ogy [19–22] and is relatively unstudied.
MDA had significant perceptual effects. Alles [106], who first
studied MDA in self-experiments, reported experiencing visual
percepts of smoke rings. However, subsequent researchers have
emphasized the unusually consistent social and emotional effects of
MDA rather than the visual changes [27,107,108]. Given that
drug-induced CEVs are more easily elicited than open-eye visual
changes, one might speculate that MDA-induced extraversion
decreases likelihood of closing eyes and experiencing visual
percepts. Nonetheless, it seems likely that the visual effects of
MDA are more subtle than those of hallucinogens such as
mescaline and psilocybin, which often produce dramatic open-eye
visual percepts [9,109].
Magnitude of CEVs after MDA was associated with lower
performance on the two measures of perceptual organization. In
Figure 8. Tilt illusion performance for individuals. Text above each plot indicates order of dosing conditions and participant number.
doi:10.1371/journal.pone.0014074.g008
Figure 9. Tilt illusion is larger for those who received MDA first.
doi:10.1371/journal.pone.0014074.g009
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condition, suggesting that individuals who saw more intense CEVs
both had poorer overall performance on these tasks and also had
greater MDA-induced changes in perceptual performance. This
finding is consistent with evidence from other populations linking
hallucinations to decreased sensory fidelity and impaired percep-
tual organization [36,40,110]. Acute effects of MDA on the
contour integration task also match acute effects previously
reported for the NMDA antagonist hallucinogen ketamine [55].
While decreased perceptual performance in MDA sessions could
be partly due to nonspecific drug effects, we were not able to find a
significant relationship between general self-report effects and
impaired perceptual performance. The association of CEVs and
uninebriated perceptual performance suggests those with poor
perceptual organization may be more likely to experience
hallucinations. Our study is not able to specify the underlying
mechanism of this potential relationship. Further research will be
needed to determine if this is the result of relatively low-level
sensory fidelity changes (such as changes in gain control of
thalamic or cortical neurons), perceptual organization effects, or
higher-level cognitive changes.
In addition to decreased perceptual ability, hallucinations have also
been linked to abnormal excitation in a number of disorders, such as
migraine and epilepsy [58,59,111]. Althoughnever previouslystudied
duringacutehallucinogeneffects, increased occipitalcortex excitation
is predicted by Ermentrout and Cowan’s model of geometric
hallucinations [63]. In keeping with this prediction, we detected
some evidence of increased occipital cortex excitation using the tilt
illusion. Specifically, the magnitude of the illusion was predicted by
dosing condition in a between-subjects comparison using only
participants’ first sessions. However, we regard this finding as
tentative. First, the effect did not seem related to magnitude of CEVs
o rs e l f - r e p o r tg e o m e t r i cv i s u a l s .S e c o n d ,i tw a sn o tr o b u s t l yd e t e c t i b l e
in planned within-subjects analyses. We restricted our analysis of tilt
illusion results to the first session because we saw a significant
sequence effect in our analysis which we interpret as possible evidence
of residual effects of MDA in the task.
Residual effects of MDA in the tilt illusion are not unprece-
dented. While not previously reported with MDA, there have been
previous reports of residual effects of MDMA in the closely related
tilt aftereffect [112,113] as well as evidence of lasting changes in
occipital cortex excitability measured with TMS or fMRI
[114,115]. In addition, some MDMA users report persisting visual
percepts [116,117]. If confirmed, the possibly increased cortical
Figure 10. Contour integration showed an interaction of
dosing condition and closed-eye visuals.
doi:10.1371/journal.pone.0014074.g010
Figure 11. Beanplot showing object recognition accuracies for
cue types in both conditions. Contours indicate probability
distribution functions with placebo in black and MDA in red. White
lines are horizontal histograms indicating distribution of accuracies.
Solid black lines indicate means for each condition and cue type.
Dotted line indicates mean for entire sample.
doi:10.1371/journal.pone.0014074.g011
Figure 12. Scatterplot object recognition accuracies showing
interaction of dosing condition and self-report closed-eye visuals.
doi:10.1371/journal.pone.0014074.g012
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plausible mechanism for the geometric pattern hallucinations
sometimes reported by such individuals.
A third factor that might contribute to the mechanism of drug-
induced hallucinations is cognitive changes. Hallucinations have
been hypothesized to be produced by increased influence of top-
down factors on perception. We found that participants made
effective use of true cues during their MDA session and, if
anything, performance in trials with false or no cues may have
been differentially impaired. However, we were not able to
confirm a statistical interaction between cue type and dosing
condition in the object recognition task. One limitation to the task
is that it did not allow us to cleanly distinguish criterion shifts from
changes in sensitivity, which may have decreased our ability to
detect drug effects. Thus, we cannot confirm or deny the role of
strengthened top-down factors in MDA-induced hallucinations.
Furthermore, the object recognition task only manipulated one
kind of top-down influence, with cues essentially functioning as
semantic primes. Each cue would be expected to activate high-
level representations of the cued object, but —because the cue had
50% accuracy— would not create a strong response bias to
indicate that the cue was correct. Nonetheless, it likely also
minimized the type of top-down attentional changes that are
normally measured, for example, in the Posner cuing task [118].
In that task, top-down changes are typically created using spatially
predictive cues. Tasks like the Posner task that manipulate the
likelihood of different responses might also be useful in studying
drug-induced hallucinations.
There were several limitations to our tests of hallucination
mechanisms that were imposed by the overall study design. To
begin with, our participants were all experienced users of MDMA
and hallucinogens. This was an ethical consideration intended to
minimize risk of idiosyncratic reaction and facilitate informed
consent. However, participants’ expectations and drug use history
may have influenced effects, limiting generalizability. Another
limitationwas thatdosingsessionswereonconsecutivedays inorder
to maximize measurement of the pharmacokinetics of a presumably
long-half-life drug while minimizing blood loss in participants.
Therefore, placebo measures may have been influenced by residual
(next day) effects of MDA in half the participants. Although such
trade-offs are a necessary part of clinical research with psychoac-
tives, they may have limited our ability to detect the acute effects of
MDA. Thus, further research with MDA will be needed in order to
confirm and extend our findings.
One potentially promising approach would be to use noise
masking and signal detection theory to examine mechanisms of
hallucinogen-induced visual changes [119–122]. This would allow
us to mathematically separate different sources of altered
efficiency, such as increased internal noise or inefficient use of
available information. Additionally, repeating these tasks with
other serotonergic hallucinogens, such as LSD and psilocybin,
might allow us to begin to better understand the relationships
between neuropharmacology of hallucinogens and their complex
phenomenology.
In conclusion, we conducted the first study of the effects of the
hallucinogen MDA in humans in over thirty years. We confirmed
that the drug does induce mystical-type experiences and, in at least
some individuals, CEVs. Magnitude of CEVs after MDA was
associated with lower performance on measures of contour
integration and object recognition, supporting a hypothesized link
between hallucinations and impairments in sensory or perceptual
processing. In contrast, we were unable to provide strong evidence
for changes in efficacy of top-down influences on perception or
acutely increased occipital cortex excitation.
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